AbbVie

News

NICE backs chemo-free CLL combination from AbbVie and Roche

Previously untreated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE recommended NHS funding for a combination of AbbVi

News

FDA grants full approval for Roche/AbbVie's Venclexta in AML...

Combination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute myeloid leukaemia, following supportive data from late-stage studies

News

FDA fast-tracks AbbVie's spinal injury drug

The FDA has fast tracked development of AbbVie’s potential spinal injury drug, elezanumab, a process that will be aided by digital analysis.

News

A healthy discussion on funding tomorrow’s treatments

Despite biosims, ulcerative colitis drugs still cost too muc...

None of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough to be cost-effective, says the Institute for Clinical and Economic Review

News

AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cance...

AbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record licensing deal involving a Chinese biotech.

News

Gilead eyes takeover of cancer biotech Tizona, despite its t...

Gilead Sciences’ run of oncology-focused deals has continued with an option to buy cancer immunotherapy specialist Tizona – even though the biotech’s lead drug candidate is alr

NICE backs chemo-free CLL combination from AbbVie and Roche

FDA grants full approval for Roche/AbbVie's Venclexta in AML...

FDA fast-tracks AbbVie's spinal injury drug

Despite biosims, ulcerative colitis drugs still cost too muc...

AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cance...

Gilead eyes takeover of cancer biotech Tizona, despite its t...

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks